AK1320 MS ( DrugBank: - )
1 disease
| ID | Disease name (Link within this page) | Number of trials |
|---|---|---|
| 70 | Spinal stenosis | 1 |
70. Spinal stenosis
Clinical trials : 95 / Drugs : 169 - (DrugBank : 61) / Drug target genes : 68 - Drug target pathways : 90
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT04483297 (ClinicalTrials.gov) | November 18, 2020 | 14/7/2020 | First-In-Human Study of AK1320 Encapsulated Microspheres (AK1320 MS) | First-In-Human Study of AK1320 Encapsulated Microspheres (AK1320 MS) In Subjects With Degenerative Spondylolisthesis and Concomitant Symptomatic Spinal Stenosis Who Are Undergoing Decompression And Single Level Instrumented Posterolateral Lumbar Autograft Fusion Surgery | Degenerative Spondylolisthesis;Spinal Stenosis | Drug: AK1320 MS;Other: Control | Asahi Kasei Pharma Corporation | Emergent Clinical Consulting, LLC | Active, not recruiting | 22 Years | 80 Years | All | 40 | Phase 1 | Canada |